- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02963324
Physiologically-based Pharmacokinetic Modeling of Ivermectin in Healthy Human Volunteers (IVMPBPK)
Physiologically-based Pharmacokinetic Modeling of Ivermectin in Healthy Human Volunteers - a Single-center, Open-label Pharmacokinetics Study
Study Overview
Detailed Description
Ivermectin (IVM) is a broad spectrum antiparasitic drug. Recent research indicates that IVM could potentially be used in malaria vector control.
The present study assesses the pharmacokinetic profile of IVM in healthy human volunteers and aims to create a physiologically-based pharmacokinetic model. This model will be used to characterize enterohepatic circulation, serve as a basis for drug-drug and drug-disease-state interaction studies, and simulations of IVM disposition in different populations, with special regard given to adolescents and children. With this, safety in individual administrations can be increased, and mass drug administration programs, e.g. oral IVM as malaria vector control, be simulated and planned to maximize the share of a population that can be included. Capillary blood concentration profiles will also be determined to assess the amount of IVM delivered to mosquitos in malaria vector control programs. Furthermore, this study will validate dried blood spot analytics of IVM which will allow easier procurement of pharmacokinetics (PK) data in the field.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland, 4031
- University Hospital Basel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Age 18-65 years old
- Caucasian male or female volunteers
- Body mass index (BMI) 18-30 kg/m2, weight ≥ 50 kg
- Full mental and legal capacity
- Signed informed consent prior to any study related procedure
- Ability to communicate in German or English, sufficient to comprehend and adhere to study protocol
- Normal physical examination, vital signs, laboratory workup, and electrocardiogram (ECG) (in the opinion of investigator)
- No history or presence of surgical or medical conditions that might interfere with absorption, distribution, metabolism, and / or elimination of study drug, and / or which might increase its toxic effects (in the opinion of investigator)
- No ongoing or recent (one month) participation in another clinical trial
- No loss of blood ≥ 250 ml within the last three months
- No known hypersensitivity to study drug or any of its constituents
- No other conditions or circumstances that might interfere with compliance with study protocol (in the opinion of investigator)
Exclusion criteria
- History or presence of hepatic or biliary disease
- History of gastrointestinal surgery, specifically cholecystectomy
- History or presence of alcohol or drug abuse
- History or presence of neurological or psychiatric comorbidities, including psychological therapy
- Other clinically significant concomitant disease states (e.g., renal disease, cardiovascular disease, etc.)
- Intake of prescribed or over-the-counter medications, herbal preparations, and / or vitamin / dietary supplements
- Clinically relevant history or presence of allergy or asthma (in the opinion of investigator)
- Female volunteers: pregnancy as confirmed by laboratory assessment; breast-feeding
- Known hypersensitivity or allergy to class of drugs or the study product
- Women with intention to become pregnant during the course of the study,
- Lack of safe contraception, defined as: female participants of childbearing potential, not using and not willing to continue using two medically reliable methods of contraception for the entire study duration, or who are not using any other method considered sufficiently reliable by the investigator in individual cases, for the duration of the study from screening visit to 30 days after end-of-study-examination.
- Please note that female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.
- Known or suspected non-compliance, drug or alcohol abuse,
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ivermectin
Single dose of ivermectin 12 mg (as 4 tablets of Stromectol (R) 3 mg) orally
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum concentration (Cmax) of ivermectin in whole blood, plasma, and capillary blood
Time Frame: Intermittent sampling for 72 hours after dosing
|
Intermittent sampling for 72 hours after dosing
|
Time to maximum concentration (Tmax) of ivermectin in whole blood, plasma, and capillary blood
Time Frame: Intermittent sampling for 72 hours after dosing
|
Intermittent sampling for 72 hours after dosing
|
Area under the curve (AUC) of ivermectin in whole blood, plasma, and capillary blood
Time Frame: Intermittent sampling for 72 hours after dosing
|
Intermittent sampling for 72 hours after dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurence of adverse events
Time Frame: For 72 hours after dosing
|
adverse events (treatment-emergent and/or leading to premature study drug discontinuation).
|
For 72 hours after dosing
|
Laboratory changes
Time Frame: For 72 hours after dosing
|
Change from baseline for clinical laboratory tests at the end of the study.
|
For 72 hours after dosing
|
Changes in electrocardiogram (ECG)
Time Frame: For 72 hours after dosing
|
Change from baseline in resting 12-channel electrocardiogram (ECG) at the end of the study.
|
For 72 hours after dosing
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stephan Krähenbühl, MD PhD, University Hospital, Basel, Switzerland
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IVMPBPK
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Ivermectin
-
Pierre Fabre DermatologyWithdrawn
-
Zydus Worldwide DMCCCatawba Research, LLCCompletedFacial RosaceaUnited States
-
Taro Pharmaceuticals USACompletedLice; Head LiceUnited States
-
Humanis Saglık Anonim SirketiCompleted
-
Assistance Publique - Hôpitaux de ParisCompletedIvermectin | Gale | Severe Forms of Scabies | Oral Parasitic DrugFrance
-
Mahidol UniversityMinistry of Health, ThailandUnknown
-
Actavis Inc.Teva Pharmaceuticals USACompleted
-
South Valley UniversityRecruiting
-
Padagis LLCCompleted